Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


2 Clin Infect Dis
1 Indian Pediatr
1 J Gen Virol
1 J Immunol
1 J Virol
1 Lancet
1 Nat Med
1 PLoS Comput Biol
2 PLoS One
20 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. WISE J
    Measles: Birmingham outbreak declared a national incident and likely to spread.
    BMJ. 2024;384:q159.

    Clin Infect Dis

  2. GROV C, Zohra F, Mirzayi C, Stief M, et al
    Sexual and Gender Minorities' Vaccine Uptake and Behavioral Change in Response to the Mpox Outbreak in the United States: August 2022 Through November 2022.
    Clin Infect Dis. 2024 Jan 23:ciad793. doi: 10.1093.
    PubMed         Abstract available

  3. ISON MG, Papi A, Athan E, Feldman RG, et al
    Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
    Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093.
    PubMed         Abstract available

    Indian Pediatr

  4. RAO M IS, Kasi SG, Dhir SK, Wadhwa A, et al
    Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2023) and Update on Immunization for Children Aged 0 Through 18 Years.
    Indian Pediatr. 2024 Jan 15:S097475591600592.
    PubMed         Abstract available

    J Gen Virol

  5. MCMILLAN CLD, Wijesundara DK, Choo JJY, Amarilla AA, et al
    Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein.
    J Gen Virol. 2024;105.
    PubMed         Abstract available

    J Immunol

  6. PULLEN RH 3RD, Sassano E, Agrawal P, Escobar J, et al
    A Predictive Model of Vaccine Reactogenicity Using Data from an In Vitro Human Innate Immunity Assay System.
    J Immunol. 2024 Jan 26:ji2300185. doi: 10.4049/jimmunol.2300185.
    PubMed         Abstract available

    J Virol

  7. DENG Y, Sheng Y, Zhang G, Sun Y, et al
    A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2.
    J Virol. 2024 Jan 25:e0165023. doi: 10.1128/jvi.01650.
    PubMed         Abstract available


  8. TERAI M, Sato T
    Individualised neoantigen cancer vaccine therapy.
    Lancet. 2024 Jan 18:S0140-6736(23)02463-7. doi: 10.1016/S0140-6736(23)02463.

    Nat Med

  9. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.

    PLoS Comput Biol

  10. GRUNNILL M, Arino J, McCarthy Z, Bragazzi NL, et al
    Modelling disease mitigation at mass gatherings: A case study of COVID-19 at the 2022 FIFA World Cup.
    PLoS Comput Biol. 2024;20:e1011018.
    PubMed         Abstract available

    PLoS One

  11. TREGNAGO D, Avancini A, Belluomini L, Trestini I, et al
    Cross-sectional survey evaluating the psychological impact of the COVID-19 vaccination campaign in patients with cancer: The VACCINATE study.
    PLoS One. 2024;19:e0290792.
    PubMed         Abstract available

  12. SOW A, Diallo C, Cherifi H
    Interplay between vaccines and treatment for dengue control: An epidemic model.
    PLoS One. 2024;19:e0295025.
    PubMed         Abstract available


  13. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  14. RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al
    Lessons learned: COVID-19 vaccinations and people with disabilities.
    Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  15. WANG CP, Lin YT, Du YZ, Zhang T, et al
    Impact of innovative immunization strategy on PCV13 vaccination coverage among children under 5 years in Weifang city, China: A retrospective study.
    Vaccine. 2024 Jan 23:S0264-410X(24)00030-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  16. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  17. CHRISTOPH R, Giovanni A, Arne S, Sebastian V, et al
    Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis.
    Vaccine. 2024 Jan 18:S0264-410X(24)00022-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

    Implications of vaccine non-specific effects on licensure of new vaccines.
    Vaccine. 2024 Jan 18:S0264-410X(24)00060-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  19. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  20. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  21. KUMWICHAR P, Chongsuvivatwong V, Vasoppakarn S, Atthakul N, et al
    Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
    Vaccine. 2024 Jan 20:S0264-410X(24)00026-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  22. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  23. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  24. CATALDI JR, Suresh K, Brewer SE, Perreira C, et al
    Boot Camp Translation using Community-Engaged messaging for adolescent Vaccination: A Cluster-Randomized trial.
    Vaccine. 2024 Jan 21:S0264-410X(24)00054-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  25. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  26. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  27. CAO H, Li H, Luan N, Zhang H, et al
    A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity.
    Vaccine. 2024 Jan 22:S0264-410X(24)00069-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  28. CLOTHIER HJ, Shetty AN, Mesfin Y, Mackie M, et al
    What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
    Vaccine. 2024 Jan 22:S0264-410X(24)00025-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  29. HADLER SC, Shefer AM, Cavallaro KF, Ebama M, et al
    Supporting National Immunization Technical Advisory Groups (NITAGs) in development of evidence-based vaccine recommendations and NITAG assessments - New tools and approaches.
    Vaccine. 2024 Jan 23:S0264-410X(24)00035-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  30. ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al
    Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
    Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  31. HARANAKA M, Young Song J, Huang KC, de Solom R, et al
    A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults?>/=?60 years of age in Japan, South Korea, and Taiwan.
    Vaccine. 2024 Jan 23:S0264-410X(24)00008-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  32. LIU R, Fan Y, Patel A, Liu H, et al
    The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
    Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.